Recently, we identified a potent four-component immunotherapy comprised of an anti-tumor antibody (“A”), half-life-extended interleukin-2 (“I”), anti-PD-1 (“P”), and a peptide vaccine (“V,” with the combination treatment abbreviated as AIPV hereafter), which cured a majority of animals in several difficult-to-treat transplanted and genetically engineered mouse models (GEMMs) of cancer (Moynihan et al., 2016). The gene discussed is PDCD1; the disease is neoplasm.